Meeting
2017 ASCO Annual Meeting
Activity of cabazitaxel in temozolomide refractory glioblastoma: Final results of a phase 2 study (C-GBM study; EudraCT 2013-001550-98 NCT 01866449).
Authors
Bernhard Heinrich
Hematological-Oncological Practice, Augsburg, Germany
Bernhard Heinrich , Richard F Schlenk , Olaf Lothar Brudler , Simone Edenhofer , Angelika Scheuerle , Ralph Naumann , Regine Mayer-Steinacker , Markus Bangerter , Lars Bullinger
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT 01866449
Citation
J Clin Oncol 35, 2017 (suppl; abstr 2056)
DOI
10.1200/JCO.2017.35.15_suppl.2056
Abstract #
2056
Poster Bd #
298
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients (pts) with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric): Results of an Australian phase II clinical trial.
First Author: Mustafa Khasraw
Poster
2022 ASCO Annual Meeting
Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to temozolomide, a phase II study (NCT03643549).
First Author: Dorota Goplen
Poster
2021 ASCO Annual Meeting
A phase II study of anlotinib combined with STUPP regimen in the treatment of patients with newly diagnosed glioblastoma (GBM).
First Author: Peijing Li
Poster
2016 ASCO Annual Meeting
Final report of randomized phase II study of two different outpatient setting regimens, vinorelbine (VNR) with cyclophosphamide (CPA) and temozolomide (TMZ) with etoposide (VP).
First Author: Atsushi Ogawa